Claims

1. The use of a pharmaceutical formulation suitable for, adapted for, and/or packaged and presented for, topical administration, comprising montelukast, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically-acceptable topical adjuvant, diluent or carrier, for the manufacture of a medicament for the healing or the recovery of a condition characterised by inflammation that is selected from an open wound or a burn of the skin or of the mucosa, or hemorrhoids, by direct topical application of said formulation to said open wound, burn or hemorrhoids,.

2. The use as claimed in Claim 1, wherein the open wound or burn comprises one or more of the group consisting of: an abrasion, a scratch, an incision, a laceration, a skin puncture, an avulsion and a blister.

3. The use as claimed in Claim 1, wherein the condition is hemorrhoids.

4. The use as claimed in Claim 1 or Claim 2, wherein the condition is a wound or burn caused by heat, a chemical, sunburn, chilblains or frostbite.

5. The use as claimed in Claim 1 or Claim 2, wherein the open wound is a consequence of a disease or a disorder.

6. The use as claimed in Claim 5, wherein the open wound is an ulcer of the skin or the mucosa.

7. The use as claimed in Claim 6, wherein the ulcer is a hard to heal ulcer of the skin or a gastric ulcer.

8. The use as claimed in Claim 5 or Claim 6, wherein the disease or disorder is ulcerative colitis.

9. The use as claimed in Claim 5 or Claim 6, wherein the disease or disorder is esophagitis or gastritis.

10. The use as claimed in any one of the preceding claims wherein the open wound results from an internal or external injury.

11. The use as claimed in any one of the preceding claims wherein the open wound or burn results from an internal or external injury to the membrane surface or comprises damage to and/or below the epidermis or the dermis.

12. The use as claimed in Claim 11, wherein the damage comprises damage to muscles, bones, joints and/or internal organs.

13. The use as claimed in any one of the preceding claims, wherein the formulation further treats the or pain and/or itching associated with the conditionor healing processes associated therewith.

14. The use as claimed in any one of the preceding claims, wherein the formulation further prevents the exudation of body fluids and/or the risk of infection resulting from the condition, and/or further prevents physiological reactions that result from healing processes.

15. The use as claimed in Claim 14, wherein the physiological reaction comprises scarring and/or melanin pigmentation.

16. The use as claimed in Claim 15, wherein the melanin pigmentation is associated with chloasma, freckles, melanosis, malar rash, another chromatosis, a skin cancer with melanoma, and/or a chromatosis that is caused by exposure to the sun.

17. The use as claimed in any one of Claims 1 to 6 or 10 to 16, wherein the topical administration is to the skin.

18. The use as claimed in any one of Claims 1 to 10, 13 or 14, wherein the topical administration is to a mucosal surface.

19. The use as claimed in any one of the preceding claims, wherein the formulation is in the form of an aqueous solution, a gel, a cream, an ointment, a lotion, a condensate, a foam or a paste.

20. The use as claimed in Claim 19, wherein the formulation further comprises a polyethylene glycol.

21. The use as claimed in Claim 20, wherein the polyethylene glycol is polyethylene glycol 400.

22. The use as claimed in Claim 15, wherein the physiological reaction comprises scarring.

23. The use as claimed in Claim 18 or Claim 22, wherein the topical administration is pulmonary administration to the mucosal surface.

24. The use as claimed in Claim 23, wherein the pulmonary administration is tracheally or bronchially.

25. The use as claimed in Claim 23 or Claim 24, wherein the pulmonary administration is to treat inhalation injury.

26. The use as claimed in any one of Claims 23 to 25, wherein the formulation is in the form of a liquid spray for inhalation.

27. The use as claimed in Claim 18 or Claim 22, wherein the topical administration is to an oral, a nasal, an ocular, a vaginal, a cervical or an anorectal mucosal surface.

28. The use as claimed in Claim 27, wherein the administration is to a vaginal, a cervical or an anorectal surface.

29. The use as claimed in any one of Claims 28, wherein the formulation is in the form of a gel.

30. The use as claimed in any one of the proceeding claims wherein the formulation further comprises at least one mussel adhesive protein which is a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof.

31. The use as claimed in any one of Claims 1 to 25 wherein the formulation is part of a kit of parts further comprising a pharmaceutical formulation including at least one mussel adhesive protein which is a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier, wherein the two formulations are each provided in a form that is suitable for administration in conjunction with the other.

32. The use as claimed in Claim 31, wherein the two formulation are suitable for sequential, separate and/or simultaneous use in the treatment of the condition.

33. The use as claimed in any one of Claims 30 to 32, wherein the at least one mussel adhesive protein is selected from the group: mefp-1 mefp-2, mefp-3, mefp-4, mefp-5, mefp-6 and combinations thereof.

34. The use as claimed in Claim 33, wherein the at least one mussel adhesive protein comprises mefp-1.